newsfilter
← Latest News
GlobeNewswire·

Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced the enrollment and dosing of more than 100 subjects in the Company's ongoing Phase 2/3 study of Tempol for the treatment of COVID-19. The Dat